Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
hsa-miR-222
Specific or universal ncRNAs
Universal ncRNAs
Class
MicroRNA
Biomarker
No
Biomarker application
Upstream regulatory factors
Not available
Downstream target
PTEN/Akt/FOXO1 signaling pathway
Cancer name
Breast Cancer
Cancer site
Breast
Treatment type
Chemotherapy
Drug
Adriamycin
Impact of wild-type ncRNA on chemotherapy resistance
Up
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway.
Tissue resource
human breast cancer cell lines MCF-7
Experiment
qRT-PCR,Western blot
Institute
the Cell Bank of the Chinese Academy of Sciences
Country
China
Continent
Asia
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.